Merck & Co., Inc. vs Direxion Daily Semiconductor Bull 3X Shares — how do they compare? Merck & Co., Inc. trades at $145.6 (market cap $351.28B), while Direxion Daily Semiconductor Bull 3X Shares trades at $139.76 (market cap $24.42B). The key difference: Merck & Co., Inc. is far larger — about 14.4× Direxion Daily Semiconductor Bull 3X Shares's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Direxion Daily Semiconductor Bull 3X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Direxion Daily Semiconductor Bull 3X Shares for 15 Days on average.
| MRK | SOXL | |
|---|---|---|
Market Cap | $351.28B | $24.42B |
Volume | 7,969,665 | 100,232,380 |
Sector | Health | Leveraged / Inverse |
52-Week High | $156.43 | $300.77 |
52-Week Low | $82.49 | $30.81 |
Typical Hold Time | 98 Days | 15 Days |
Enterprise Value | $398.04B | — |
Dividend Yield | 2.39% | — |
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal and key support at $140. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.14. Revenue grew to $65.01B in 2025, and net income reached $18.25B, though the P/E ratio is elevated at 113.9. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook for MRK is mixed, with solid fundamentals and analyst optimism countered by high valuation and bearish technicals. The consensus price target of $158.78 suggests upside potential, but investors face risks from competitive pressures and integration challenges from recent M&A activity. Earnings growth and pipeline developments remain key catalysts.
SOXL, the Direxion Daily Semiconductor Bull 3X ETF, is trading at $142.52, down 10.31% with a bearish technical signal. The semiconductor sector faces volatility, with mixed news including recent chip stock rallies and concerns about AI funding and regulatory tariffs. Technical indicators show neutral oscillators but bearish overall momentum, with key support at $134 and resistance at $153.
Outlook remains cautious due to leveraged ETF risks and semiconductor sector volatility. Investment opportunity exists for bullish semiconductor bets amid strong AI demand, but risks include high leverage decay, regulatory headwinds, and crowded trading positioning. Timing is critical given recent sharp rebounds and potential near-term drawdowns.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →SOXL is a leveraged ETF that seeks daily investment results corresponding to 300% of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bullish (long) position on the semiconductor sector. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXL →